Urogenital Tract Infection

Table. 1.

Correlation between urological drugs with COVID-19

Medication Considerations Drug-drug interaction related to COVID-19
α-blockers Potential to decrease acute respiratory distress syndrome. None
5α-reductase inhibitors Mixed reports that they will play a protective or worsening role. None
PDE-5 inhibitors Theoretically, respiratory symptoms of COVID-19 can be reduced. Avoid concomitant use with lopinavir/ritonavir.

PDE-5: phosphodiesterase-5.

Urogenit Tract Infect 2022;17:31-5 https://doi.org/10.14777/uti.2022.17.2.31
© 2022 Urogenit Tract Infect